{
  "status_code": 200,
  "request": {
    "description": "Comprehensive genomic profiling/NGS in solid cancers.",
    "research_questions": [
      "What is the incidence and prevalence of advanced cancers in Europe and other key jurisdictions?\n-   Focus on France, Italy, Spain, Belgium, Switzerland, UK; also include data for rest of Europe and Brazil, Chile, Columbia, Mexico, Canada.",
      "What are EMA-approved and ESMO guideline-recommended biomarker-guided treatments in advanced cancer types?\n-   Focus on the use of genomic testing in non-small-cell lung cancer, colorectal cancer, malignant melanoma, ovarian cancer and breast cancer, to reflect the different number and type of biomarkers associated with each type of malignant disease",
      "What are the types of precision medicine approaches in advanced cancers in Europe (that is, finding treatments that are effective for specific genomic biomarkers in a solid tumor)?\n-   Targeted therapies for specific cancer types\n-   Tissue-agnostic (pan-cancer) therapies\n-   Multi-tumor type targeted therapies\n-   Biomarker-based immunotherapy approaches\n-   Emerging molecularly targeted therapies and ongoing clinical trials",
      "What are the unmet needs with current practice of genomic testing in advanced cancers in Europe?\n-   What are the existing technologies for genomic testing?\n-   What are the technology requirements for identification of specific types of genomic aberrations?\n-   What are the key unmet needs in genomic testing workup approaches in current clinical practice?\n-   What are the challenges faced by people trying to implement genomic testing for rate mutations?",
      "What is the clinical utility of comprehensive genome profiling (CGP)?\n-   How far does CGP offer broader coverage of medically necessary biomarkers than more traditional methods of identifying mutations, such as polymerase chain reaction (PCR), chromosomal microarray (CMA) \u00c2\u00a0or small gene panel assays?\n-   Is the accuracy of CGP higher than traditional approaches in detecting biomarkers?\n-   Does the use of CGP improve patient outcomes, for example, do patients respond better to, or live longer with, therapies that target the patient's specific mutation?\n-   Does the use of CGP mean that fewer biopsy samples are needed?\n-   Does the use of CGP increase the number of patients who are eligible to be enrolled in clinical trials of new targeted therapies?",
      "Economic impact\n-   What is the budget impact of adopting CGP compared with traditional genetic testing?\n-   What is the cost-effectiveness of CGP?"
    ],
    "mock": false
  },
  "response": {
    "refined_description": "This systematic review will evaluate the use of comprehensive genomic profiling (CGP), including next-generation sequencing (NGS), in adults (\u226518 years) diagnosed with advanced (stage III/IV or metastatic) solid tumors. The geographic focus is on France, Italy, Spain, Belgium, Switzerland, and the UK, with supplemental data from the rest of Europe, Brazil, Chile, Colombia, Mexico, and Canada. The review will consider studies published from 2013 onwards, reflecting the era when NGS and CGP became more widely implemented in clinical care. We will include studies conducted in hospital, cancer center, or national/regional healthcare settings. Studies limited to pediatric cancers, hematological malignancies, or studies not reporting separate results for advanced/metastatic solid tumors are out of scope. Single case reports and preclinical research are also excluded.",
    "refined_research_questions": [
      "Among adult patients (\u226518 years) with advanced or metastatic solid cancers, what are the reported incidence and prevalence rates in France, Italy, Spain, Belgium, Switzerland, UK, rest of Europe, Brazil, Chile, Colombia, Mexico, and Canada (2013-present)?",
      "Which EMA-approved and ESMO guideline-recommended, biomarker-guided therapies are currently available for advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, ovarian cancer, and breast cancer in Europe, and which associated genomic biomarkers are routinely tested for using NGS?",
      "What types of precision medicine approaches based on genomic biomarkers are available for adults with advanced solid tumors in Europe, including (a) targeted therapies for specific cancer types, (b) tissue-agnostic/pan-cancer therapies, (c) multi-tumor type therapies, and (d) biomarker-based immunotherapy?",
      "What current genomic testing technologies (e.g., NGS, gene panels, PCR, CMA) are used for advanced solid tumors in Europe, and what are the key technical, clinical, and implementation challenges or unmet needs associated with their use?",
      "What evidence exists for the clinical utility of CGP by NGS compared with traditional methods (PCR, CMA, small gene panels) in adults with advanced solid tumors; specifically: (a) coverage of actionable biomarkers, (b) analytic accuracy, (c) impact on treatment selection, (d) impact on patient outcomes (response rates, survival), (e) impact on the number of biopsies required, and (f) impact on eligibility for targeted therapy clinical trials?",
      "What are the reported economic outcomes\u2014including budget impact and cost-effectiveness\u2014of implementing CGP compared to traditional genetic testing modalities for adults with advanced solid cancers in the stated jurisdictions?"
    ],
    "explanation": "The project description was made more precise by specifying adult patients, advanced solid cancers, covered countries, included settings, publication timeframe, and out-of-scope populations and study types. Each research question was rephrased to clarify the PICO elements (Population, Intervention, Comparator, Outcomes), to enable more accurate inclusion/exclusion decisions during screening, and to split compound questions into subcomponents where possible."
  }
}